Morioka Daisuke, Tanaka Kuniya, Matsuo Ken-ichi, Takeda Kazuhisa, Ueda Michio, Sugita Mitsutaka, Nagano Yasuhiko, Endo Itaru, Sekido Hitoshi, Togo Shinji, Shimada Hiroshi
Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.
Ann Surg Oncol. 2006 Nov;13(11):1500-10. doi: 10.1245/s10434-006-9204-8. Epub 2006 Sep 29.
To determine whether or not the Milan criteria (MC) should be used to determine the applicability of liver transplantation (LT) as a first-line treatment for patients with cirrhosis with hepatocellular carcinoma (HCC) who are able to endure hepatectomy.
Retrospective analysis of 82 patients with cirrhosis with HCC who were treated by hepatectomy without LT at our institution between 1990 and 2003.
Of these 82 patients, 48 met the MC. Proportional hazard regression analyses to determine the independent prognostic factors for postoperative cumulative patient and disease-free survival showed that meeting the MC is the strongest prognostic factor for both patient and disease-free survival. The cumulative patient and disease-free survival rates were 76.7% and 28.9%, respectively, at 5 years in patients who met the MC. The cumulative disease-free survival was markedly inferior to those in previously reported series of LT for HCC who met the MC, but the cumulative patient survival was comparable to those in the previously reported series. A comparison of cumulative postoperative survival between patients who met the MC and fulfilled all five factors listed below and patients who met the MC but did not fulfill any of the five factors demonstrated that the latter patients showed statistically significantly worse postoperative patient survival than the former. The five factors included: Model for End-Stage Liver Disease score < 10, indocyanine green retention rate at 15 minutes < 20%, absence of microscopic fibrous capsular invasion and microscopic intrahepatic metastases, and earlier grade (T1 or T2) of American Joint Committee on Cancer tumor classification.
The MC should not be used to determine the applicability of LT as a first-line treatment for patients with HCC considered able to endure hepatectomy. However, modifying MC with some clinicopathological factors could satisfy the appropriate criteria for applying LT as a first-line treatment for these patients.
确定米兰标准(MC)是否应用于判定肝移植(LT)作为一线治疗手段对能够耐受肝切除术的肝硬化合并肝细胞癌(HCC)患者的适用性。
回顾性分析1990年至2003年间在我院接受肝切除术而非LT治疗的82例肝硬化合并HCC患者。
这82例患者中,48例符合米兰标准。通过比例风险回归分析确定术后累积患者生存率和无病生存率的独立预后因素,结果显示符合米兰标准是患者生存率和无病生存率最强的预后因素。符合米兰标准的患者5年累积患者生存率和无病生存率分别为76.7%和28.9%。累积无病生存率明显低于先前报道的符合米兰标准的HCC肝移植系列研究中的生存率,但累积患者生存率与之相当。对符合米兰标准并满足以下所有五个因素的患者与符合米兰标准但未满足任何一个因素的患者的术后累积生存率进行比较,结果显示后者术后患者生存率在统计学上显著低于前者。这五个因素包括:终末期肝病模型评分<10、15分钟吲哚菁绿潴留率<20%、无微小纤维包膜侵犯和微小肝内转移、美国癌症联合委员会肿瘤分类的早期分级(T1或T2)。
米兰标准不应被用于判定肝移植作为一线治疗手段对被认为能够耐受肝切除术的HCC患者的适用性。然而,用一些临床病理因素对米兰标准进行修正可满足将肝移植作为这些患者一线治疗手段的适当标准。